Protein C and Antithrombin Levels in Surgical and Septic Patients

  • Y. Sakr
  • N. C. M. Youssef
  • K. Reinhart
Conference paper


Activation of blood coagulation is a common observation in patients with sepsis. The clinical manifestations of an activated coagulation system depend on the degree of pro-coagulant conditions and may lead to overt disseminated intravascular coagulation (DIC), consumption coagulopathy, defibrination syndrome, and purpura fulminans. The protein C anticoagulant pathway regulates thrombin formation, prevents microvascular thrombosis, and has anti-inflammatory and profibrinolytic properties. Decreased plasma levels of antithrombin and protein C can occur in a variety of clinical conditions associated with DIC, such as sepsis, trauma, and after surgical interventions. Recent data suggest that in surgical patients admitted to the intensive care unit (ICU), antithrombin and protein C levels are low, and it has been suggested that antithrombin and protein C levels may have a potential role as predictors of outcome in critically ill patients.


Severe Sepsis Disseminate Intravascular Coag Sequential Organ Failure Assessment Score Intensive Care Unit Mortality Drotrecogin Alfa 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hoffman (2005) Hematology: Basic Principles and Practice, 4th ed. Churchill Livinsgstone, PhiladelphiaGoogle Scholar
  2. 2.
    Esmon C (2000) The protein C pathway. Crit Care Med 28:S44–S48PubMedCrossRefGoogle Scholar
  3. 3.
    Esmon CT (2003) The protein C pathway. Chest 124:26S–32SPubMedCrossRefGoogle Scholar
  4. 4.
    Dempfle CE (2004) Coagulopathy of sepsis. Thromb Haemost 91:213–224PubMedGoogle Scholar
  5. 5.
    Levi M, ten Cate H (1999) Disseminated intravascular coagulation. N Engl J Med 341: 586–592PubMedCrossRefGoogle Scholar
  6. 6.
    Levi M, Keller TT, van Gorp E, ten Cate H (2003) Infection and inflammation and the coagulation system. Cardiovasc Res 60:26–39PubMedCrossRefGoogle Scholar
  7. 7.
    LaRosa SP, Opal SM, Utterback B, et al (2006) Decreased protein C, protein S, and antithrombin levels are predictive of poor outcome in Gram-negative sepsis caused by Burkholderia pseudomallei. Int J Infect Dis 10:25–31PubMedCrossRefGoogle Scholar
  8. 8.
    Karamarkovic A, Radenkovic D, Milic N, Bumbasirevic V, Stefanovic B (2005) Protein C as an early marker of severe septic complications in diffuse secondary peritonitis. World J Surg 29:759–765PubMedCrossRefGoogle Scholar
  9. 9.
    Pettila V, Pentti J, Pettila M, Takkunen O, Jousela I (2002) Predictive value of antithrombin III and serum C-reactive protein concentration in critically ill patients with suspected sepsis. Crit Care Med 30:271–275PubMedCrossRefGoogle Scholar
  10. 10.
    Matthay MA, Ware LB (2004) Plasma protein C levels in patients with acute lung injury: prognostic significance. Crit Care Med 32:S229–S232PubMedCrossRefGoogle Scholar
  11. 11.
    Mesters RM, Heiterbrand J, Utterback BG, et al (2000) Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications. Crit Care Med 28:2209–2216PubMedCrossRefGoogle Scholar
  12. 12.
    Brunkhorst F, Sakr Y, Hagel S, Reinhart K (2007) Protein C concentrations correlate with organ dysfunction and predict outcome independent of the presence of sepsis. Anesthesiology 107:15–23PubMedCrossRefGoogle Scholar
  13. 13.
    Sakr Y, Reinhart K, Hagel S, Kientopf M, Brunkhorst F (2007) Antithrombin levels, morbidity, and mortality in a surgical intensive care unit. Anesth Analg 105:715–723PubMedCrossRefGoogle Scholar
  14. 14.
    Boldt J, Papsdorf M, Rothe A, Kumle B, Piper S (2000) Changes of the hemostatic network in critically ill patients — is there a difference between sepsis, trauma, and neurosurgery patients? Crit Care Med 28:445–450PubMedCrossRefGoogle Scholar
  15. 15.
    Wilson RF, Mammen EF, Tyburski JG, Warsow KM, Kubinec SM (1996) Antithrombin levels related to infections and outcome. J Trauma 40:384–387PubMedCrossRefGoogle Scholar
  16. 16.
    Fourrier F, Chopin C, Goudemand J, et al (1992) Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 101:816–823PubMedCrossRefGoogle Scholar
  17. 17.
    Ranucci M, Frigiola A, Menicanti L, Ditta A, Boncilli A, Brozzi S (2005) Postoperative antithrombin levels and outcome in cardiac operations. Crit Care Med 33:355–360PubMedCrossRefGoogle Scholar
  18. 18.
    Mammen EF (1998) Antithrombin: its physiological importance and role in DIC. Semin Thromb Hemost 24:19–25PubMedCrossRefGoogle Scholar
  19. 19.
    Dhainaut JF, Shorr AF, Macias WL, et al (2005) Dynamic evolution of coagulopathy in the first day of severe sepsis: relationship with mortality and organ failure. Crit Care Med 33: 341–348PubMedCrossRefGoogle Scholar
  20. 20.
    Kinasewitz GT, Yan SB, Basson B, et al (2004) Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569]. Crit Care 8:R82–R90PubMedCrossRefGoogle Scholar
  21. 21.
    Macias WL, Nelson DR (2004) Severe protein C deficiency predicts early death in severe sepsis. Crit Care Med 32:S223–S228PubMedCrossRefGoogle Scholar
  22. 22.
    Yan SB, Heiterbrand JD, Hartman DL, Wright TJ, Bernard GR (2001) Low levels of protein C are associated with poor outcome in severe sepsis. Chest 120:915–922PubMedCrossRefGoogle Scholar
  23. 23.
    Mammen EF, Koets MH, Washington BC, et al (1985) Hemostasis changes during cardiopulmonary bypass surgery. Semin Thromb Hemost 11:281–292PubMedCrossRefGoogle Scholar
  24. 24.
    Randolph AG, Guyatt GH, Calvin JE, Doig G, Richardson WS (1998) Understanding articles describing clinical prediction tools. Evidence Based Medicine in Critical Care Group. Crit Care Med 26:1603–1612PubMedCrossRefGoogle Scholar
  25. 25.
    Uchiba M, Okajima K (1997) Antithrombin III (AT III) prevents LPS-induced pulmonary vascular injury: novel biological activity of AT III. Semin Thromb Hemost 23:583–590PubMedCrossRefGoogle Scholar
  26. 26.
    Harada N, Okajima K, Kushimoto S, Isobe H, Tanaka K (1999) Antithrombin reduces ischemia/reperfusion injury of rat liver by increasing the hepatic level of prostacyclin. Blood 93:157–164PubMedGoogle Scholar
  27. 27.
    Ostrovsky L, Woodman RC, Payne D, Teoh D, Kubes P (1997) Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion. Circulation 96:2302–2310PubMedGoogle Scholar
  28. 28.
    Mizutani A, Okajima K, Uchiba M, et al (2003) Antithrombin reduces ischemia/reperfusioninduced renal injury in rats by inhibiting leukocyte activation through promotion of prostacyclin production. Blood 101:3029–3036PubMedCrossRefGoogle Scholar
  29. 29.
    Mammen EF (1998) Antithrombin III and sepsis. Intensive Care Med 24:649–650PubMedCrossRefGoogle Scholar
  30. 30.
    Warren BL, Eid A, Singer P, et al (2001) Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 286:1869–1878PubMedCrossRefGoogle Scholar
  31. 31.
    Wiedermann CJ, Hoffmann JN, Juers M, et al (2006) High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety. Crit Care Med 34:285–292PubMedCrossRefGoogle Scholar
  32. 32.
    Eisele B, Lamy M, Thijs LG, et al (1998) Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med 24:663–672PubMedCrossRefGoogle Scholar
  33. 33.
    Bernard GR, Vincent JL, Laterre PF, et al (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699–709PubMedCrossRefGoogle Scholar
  34. 34.
    Dhainaut JF, Laterre PF, Janes JM, et al (2003) Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple-organ dysfunction: data from the PROWESS trial. Intensive Care Med 29:894–903PubMedGoogle Scholar
  35. 35.
    Abraham E, Laterre PF, Garg R, et al (2005) Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 353:1332–1341PubMedCrossRefGoogle Scholar
  36. 36.
    Vincent JL, Bernard GR, Beale R, et al (2005) Drotrecogin alfa (activated) treatment in severe sepsis from global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment. Crit Care Med 33:2266–2277PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media Inc. 2008

Authors and Affiliations

  • Y. Sakr
    • 1
  • N. C. M. Youssef
    • 1
  • K. Reinhart
    • 1
  1. 1.Dept of Anesthesiology and Intensive CareFriedrich-Schiller UniversityJenaGermany

Personalised recommendations